ByteDance, the parent company of TikTok, is moving to spin off its artificial intelligence drug discovery business as a standalone entity seeking independent financing. This strategic pivot marks a significant moment for the industry known as AI for Science (AI4S), as one of the world’s most aggressive technology giants acknowledges that the pace of biological research cannot be forced into the rapid-fire iteration cycles of the internet. The decision comes amid a talent exodus, including core members like Gu Quanquan and Xiao Wenzhi, who have recently left to launch their own startups.
Founded in 2021 within the experimental "Seed" division, ByteDance’s AI pharmaceutical team was built to tackle the hardest problems in biology, from protein structure prediction to small-molecule generation. However, the unit has faced a fundamental cultural friction: the healthcare industry’s "Double Ten" rule—ten years and one billion dollars for a single drug—clashes violently with the high-pressure, quarterly-driven culture of a social media behemoth. By spinning off the unit, ByteDance seeks to decouple these conflicting timelines while allowing the new entity to adopt an incentive structure tailored to the long-haul nature of biotech.
Technically, the unit has shown promise. Operating under the brand Anew Labs, the team achieved a global first by using small molecules to block three trimers of the IL-17 cytokine family, a target long considered "undruggable" by traditional pharmaceutical methods. Despite these breakthroughs, the transition from successful lab models to clinical success remains the industry's greatest hurdle. ByteDance’s move follows a broader trend among Chinese tech titans, such as Baidu’s spin-off of its Kunlun AI chip unit and Kuaishou’s plans for its Kling AI division, as they seek to offload high-expenditure, long-cycle R&D onto private capital.
While the new entity will remain under ByteDance’s control, the shift highlights a maturation of the AI4S sector. The global market for AI-driven drug discovery is expected to approach $3 billion by 2026, yet secondary markets have recently cooled toward AI biotech firms. Investors are no longer satisfied with "conceptual validation"; they are now demanding robust clinical pipeline data. For ByteDance, the spin-off is a calculated retreat from direct management of a high-risk venture, ensuring that while it retains a stake in a potential medical revolution, it is no longer the sole bearer of its immense burn rate.